Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences

Monday, February 27, 2017 2:06 PM UTC

CAMBRIDGE, Mass., Feb. 27, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017, to discuss its fourth quarter and full-year 2016 financial results and other business highlights.

To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 79789689. The webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com.

March Investor Conferences
In addition, the company will be participating in the following March conferences:

Cowen and Company 37th Annual Health Care Conference (fireside chat format) on Monday, March 6, 2017 at 4:40 p.m. ET in New York City; and,
Oppenheimer 27th Annual Healthcare Conference (fireside chat format) on Tuesday, March 21, 2017 at 9:10 a.m. ET in New York City.

Replays of the webcasts of the presentations can be accessed at the investor section of the Company’s website at http://www.epizyme.com.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company’s proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contacts:
 
Investors
Monique Allaire, THRUST IR
[email protected]
(617) 895-9511

Media
Paul Kidwell
[email protected]
(617) 680-1088

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences

Editor's Picks

Welcome to EconoTimes